Company CureVac N.V.

Equities

CVAC

NL0015436031

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 09:43:08 2025-06-16 am EDT			5-day change	1st Jan Change
5.515 ^USD	-0.99%		+26.30%	+63.34%

Jun. 13	Jefferies Downgrades CureVac to Hold From Buy, $5 Price Target	MT
Jun. 13	CUREVAC : Downgraded to Neutral by Jefferies	ZD

Business description: CureVac N.V.

CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cellâs intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).

Number of employees: 904

Sales by Activity: CureVac N.V.

Fiscal Period: December	2020	2021	2022	2023	2024
Discovery and Development of Biotechnological Applications	48.87M	103M	67.42M	53.76M	535M

See all business segments

Geographical breakdown of sales: CureVac N.V.

Fiscal Period: December	2020	2021	2022	2023	2024
Belgium	8.81M	74.3M	62.26M	47.13M	520M
Switzerland	695K	919K	3.37M	5.42M	12.95M
Netherlands	2.63M	1.77M	1.79M	1.2M	2.38M
Others	-	-	-	8K	-
Germany	1.88M	26M	-	-	-
United States	34.85M	-	-	-	-

See all geographic segments

Executive Committee: CureVac N.V.

Manager	Title	Age	Since
Alexander Zehnder CEO	Chief Executive Officer	55	2023-03-27
Axel-Sven Malkomes DFI	Director of Finance/CFO	58	2024-11-10
Myriam Mendila CTO	Chief Tech/Sci/R&D Officer	59	-
Sarah Fakih IRC	Investor Relations Contact	-	-
Malte Greune COO	Chief Operating Officer	60	2021-06-30

See CUREVAC N.V. governance

Composition of the Board of Directors: CureVac N.V.

Director	Title	Age	Since
Baron Jean Stéphenne CHM	Chairman	74	2015-07-31
Mathias Hothum BRD	Director/Board Member	59	2015-07-31
Craig Tooman BRD	Director/Board Member	59	2019-05-31
Viola Bronsema BRD	Director/Board Member	62	2020-07-31
Klaus Schollmeier BRD	Director/Board Member	68	2022-06-21
Debra Stephanie Barker BRD	Director/Board Member	62	2022-06-21
Michael Brosnan BRD	Director/Board Member	70	2023-06-18
Birgit Hofmann BRD	Director/Board Member	59	2024-06-23
Mehdi Shahidi BRD	Director/Board Member	-	2024-08-31

Composition of the Board of Directors

Shareholders: CureVac N.V.

Name	Equities	%	Valuation
dievini Hopp BioTech holding GmbH & Co. KG 31.29 %	70,181,760	31.29 %	314 M $
Government of Germany 13.32 %	29,871,441	13.32 %	134 M $
GSK PLC 7.397 %	16,591,937	7.397 %	74 M $
Dietmar Hopp 4.589 %	10,294,503	4.589 %	46 M $
Zweite DH Verwaltungs GmbH 1.518 %	3,404,672	1.518 %	15 M $

List of CUREVAC N.V. shareholders

Company details: CureVac N.V.

CureVac NV

Friedrich-Miescher-Strasse 15

72076, Tübingen

+49 7071 9883 0

http://www.curevac.com

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
CUREVAC N.V.	-0.54%	+26.30%	+51.77%	-58.59%	1.25B
LONZA GROUP AG	-0.58%	-1.42%	+20.22%	+16.57%	49.5B
IQVIA HOLDINGS INC.	-1.41%	+3.00%	-26.26%	-22.38%	27.14B
CELLTRION, INC.	-1.89%	+2.53%	-4.26%	+20.14%	26.06B
EUROFINS SCIENTIFIC SE	-0.40%	+2.63%	+14.18%	-21.26%	12.53B
TEMPUS AI, INC.	+0.07%	+14.84%	+77.09%	-	12.34B
ICON PUBLIC LIMITED COMPANY	-0.97%	+4.71%	-53.51%	-29.15%	11.57B
MODERNA, INC.	-2.49%	-2.88%	-80.95%	-79.25%	10.31B
ASCENDIS PHARMA A/S	-0.07%	-1.31%	+33.81%	+105.31%	10.31B
QIAGEN N.V.	-0.59%	+3.58%	+8.18%	+0.88%	10.2B
Average	-0.88%	+5.12%	+4.03%	-7.52%	17.12B
Weighted average by Cap.	-0.94%	+2.09%	+2.04%	+2.13%